Summary
GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes -
Click for report details: http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options
- Disease overview, as well as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC breast cancer market from 2013 to 2020
- Major marketed products in the APAC region along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes -
Click for report details: http://www.radiantinsights.com/research/breast-cancer-therapeutics-in-asia-pacific-markets-to-2020-novel-her-2-positive-therapies-provide-diversified-treatment-options
- Disease overview, as well as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC breast cancer market from 2013 to 2020
- Major marketed products in the APAC region along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
